Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hartford Hospital
With
Neuronetics
We expected to enroll five patients with GAD who failed to respond to a sham (placebo) TMS intervention. In this pilot study we enrolled three participants into a protocol including 10 rTMS sessions (twice a week for five weeks) and one into a protocol including 15 rTMS sessions (three times a week for five weeks). Assessments occurred at pretreatment and at posttreatment.
Age
18–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Participated in the study DIEF003523.1, received sham "placebo" TMS and achieved \< 50% improvement in HARS at 3 month follow-up.
Fluency in English
Capacity to understand the nature of the study and willingness to sign informed consent form
You may not be if
History of epilepsy or head trauma (LOC \> 5 minutes) within the past 6 months
Lifetime history of increased intracranial pressure, seizure disorder, stroke, brain tumor, multiple sclerosis, or brain surgery
A review of patient medications by the study physician indicates an increased risk of seizure
An active autoimmune, endocrine, viral, or vascular disorder affecting the brain; any unstable cardiac disease; hypertension; or severe renal or liver insufficiency
Substance use disorder or PTSD within the past 6 months
